作者
John W Eikelboom, Stuart J Connolly, Jackie Bosch, Gilles R Dagenais, Robert G Hart, Olga Shestakovska, Rafael Diaz, Marco Alings, Eva M Lonn, Sonia S Anand, Petr Widimsky, Masatsugu Hori, Alvaro Avezum, Leopoldo S Piegas, Kelley RH Branch, Jeffrey Probstfield, Deepak L Bhatt, Jun Zhu, Yan Liang, Aldo P Maggioni, Patricio Lopez-Jaramillo, Martin O’Donnell, Ajay K Kakkar, Keith AA Fox, Alexander N Parkhomenko, Georg Ertl, Stefan Störk, Matyas Keltai, Lars Ryden, Nana Pogosova, Antonio L Dans, Fernando Lanas, Patrick J Commerford, Christian Torp-Pedersen, Tomek J Guzik, Peter B Verhamme, Dragos Vinereanu, Jae-Hyung Kim, Andrew M Tonkin, Basil S Lewis, Camilo Felix, Khalid Yusoff, P Gabriel Steg, Kaj P Metsarinne, Nancy Cook Bruns, Frank Misselwitz, Edmond Chen, Darryl Leong, Salim Yusuf
发表日期
2017/10/5
期刊
New England Journal of Medicine
卷号
377
期号
14
页码范围
1319-1330
出版商
Massachusetts Medical Society
简介
Background
We evaluated whether rivaroxaban alone or in combination with aspirin would be more effective than aspirin alone for secondary cardiovascular prevention.
Methods
In this double-blind trial, we randomly assigned 27,395 participants with stable atherosclerotic vascular disease to receive rivaroxaban (2.5 mg twice daily) plus aspirin (100 mg once daily), rivaroxaban (5 mg twice daily), or aspirin (100 mg once daily). The primary outcome was a composite of cardiovascular death, stroke, or myocardial infarction. The study was stopped for superiority of the rivaroxaban-plus-aspirin group after a mean follow-up of 23 months.
Results
The primary outcome occurred in fewer patients in the rivaroxaban-plus-aspirin group than in the aspirin-alone group (379 patients [4.1%] vs. 496 patients [5.4%]; hazard ratio, 0.76; 95% confidence interval [CI], 0.66 to 0.86; P<0.001; z=−4.126), but major bleeding events …
学术搜索中的文章
JW Eikelboom, SJ Connolly, J Bosch, GR Dagenais… - New England Journal of Medicine, 2017